Evaluating Hip Osteoarthritis as a Risk Factor for Immune Checkpoint Inhibitor–Induced Inflammatory Arthritis

Rebecca Fitzpatrick; Shadpour Demehri; Joseph Murray; Julie R. Brahmer; Elena Ghotbi; Durrant Barasa; Clifton O. Bingham; Ami A. Shah; Laura C. Cappelli

doi:10.3899/jrheum.2025-0808.C1

Evaluating Hip Osteoarthritis as a Risk Factor for Immune Checkpoint Inhibitor–Induced Inflammatory Arthritis

Rebecca Fitzpatrick
, Shadpour Demehri
, Joseph Murray
, Julie R. Brahmer
, Elena Ghotbi
, Durrant Barasa
, Clifton O. Bingham
, Ami A. Shah
, Laura C. Cappelli

School of Medicine

Research output: Contribution to journal › Comment/debate › peer-review

Abstract

In the originally published online version of this article, refer ence 8 was missing from the list of references. The missing refer ence has now been added: “8. Cunningham-Bussel A, Wang J, Prisco LC, et al. Predictors of rheumatic immune-related adverse events and de novo inflammatory arthritis after immune check point inhibitor treatment for cancer. Arthritis Rheumatol 2022;74:527-40.” This correction applies only to the February 1 2026 First Release. The complete list of references appears in the print and online issues.

Original language	English (US)
Pages (from-to)	716
Number of pages	1
Journal	Journal of Rheumatology
Volume	53
Issue number	6
DOIs	https://doi.org/10.3899/jrheum.2025-0808.C1
State	Published - Jun 2026

ASJC Scopus subject areas

Rheumatology
Immunology and Allergy
Immunology

Access to Document

10.3899/jrheum.2025-0808.C1

Cite this

@article{816c039351584b26be1beee177377dc4,

title = "Evaluating Hip Osteoarthritis as a Risk Factor for Immune Checkpoint Inhibitor{\textendash}Induced Inflammatory Arthritis",

abstract = "In the originally published online version of this article, refer ence 8 was missing from the list of references. The missing refer ence has now been added: {\textquotedblleft}8. Cunningham-Bussel A, Wang J, Prisco LC, et al. Predictors of rheumatic immune-related adverse events and de novo inflammatory arthritis after immune check point inhibitor treatment for cancer. Arthritis Rheumatol 2022;74:527-40.{\textquotedblright} This correction applies only to the February 1 2026 First Release. The complete list of references appears in the print and online issues.",

author = "Rebecca Fitzpatrick and Shadpour Demehri and Joseph Murray and Brahmer, \{Julie R.\} and Elena Ghotbi and Durrant Barasa and Bingham, \{Clifton O.\} and Shah, \{Ami A.\} and Cappelli, \{Laura C.\}",

note = "Publisher Copyright: Copyright {\textcopyright} 2026 by the Journal of Rheumatology",

year = "2026",

month = jun,

doi = "10.3899/jrheum.2025-0808.C1",

language = "English (US)",

volume = "53",

pages = "716",

journal = "Journal of Rheumatology",

issn = "0315-162X",

publisher = "Journal of Rheumatology",

number = "6",

}

TY - JOUR

T1 - Evaluating Hip Osteoarthritis as a Risk Factor for Immune Checkpoint Inhibitor–Induced Inflammatory Arthritis

AU - Fitzpatrick, Rebecca

AU - Demehri, Shadpour

AU - Murray, Joseph

AU - Brahmer, Julie R.

AU - Ghotbi, Elena

AU - Barasa, Durrant

AU - Bingham, Clifton O.

AU - Shah, Ami A.

AU - Cappelli, Laura C.

PY - 2026/6

Y1 - 2026/6

N2 - In the originally published online version of this article, refer ence 8 was missing from the list of references. The missing refer ence has now been added: “8. Cunningham-Bussel A, Wang J, Prisco LC, et al. Predictors of rheumatic immune-related adverse events and de novo inflammatory arthritis after immune check point inhibitor treatment for cancer. Arthritis Rheumatol 2022;74:527-40.” This correction applies only to the February 1 2026 First Release. The complete list of references appears in the print and online issues.

AB - In the originally published online version of this article, refer ence 8 was missing from the list of references. The missing refer ence has now been added: “8. Cunningham-Bussel A, Wang J, Prisco LC, et al. Predictors of rheumatic immune-related adverse events and de novo inflammatory arthritis after immune check point inhibitor treatment for cancer. Arthritis Rheumatol 2022;74:527-40.” This correction applies only to the February 1 2026 First Release. The complete list of references appears in the print and online issues.

UR - https://www.scopus.com/pages/publications/105040875626

UR - https://www.scopus.com/pages/publications/105040875626#tab=citedBy

U2 - 10.3899/jrheum.2025-0808.C1

DO - 10.3899/jrheum.2025-0808.C1

M3 - Comment/debate

C2 - 41985925

AN - SCOPUS:105040875626

SN - 0315-162X

VL - 53

SP - 716

JO - Journal of Rheumatology

JF - Journal of Rheumatology

IS - 6

ER -

Evaluating Hip Osteoarthritis as a Risk Factor for Immune Checkpoint Inhibitor–Induced Inflammatory Arthritis

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this